Pfizer Inc.
Dosage regimen for MAdCAM antagonists
Last updated:
Abstract:
The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.
Status:
Grant
Type:
Utility
Filling date:
6 Jan 2016
Issue date:
1 Dec 2020